Cancer therapies targeting specific molecular subtypes of the disease allow physicians to tailor treatment to a patient's individual molecular profile. But scientists are finding that in many types of cancer the molecular subtypes are more varied than previously thought and contain further genetic alterations that can affect a patient's response ...

Patients with head and neck cancer and a low haemoglobin (Hb) level do not respond well to radiotherapy and therefore both control of their tumour and disease-free survival are compromised. Now researchers from The Netherlands have found that the problems caused by low Hb in these patients can be overcome ...

Chemotherapy is a major first line defense against breast cancer. However a patient's response is often variable and unpredictable. A study published in BioMed Central's open access journal BMC Medical Genomics shows that 'gene expression signatures' for TOP2A and β-tubulin can be used to predict the outcome of chemotherapy. The ...

Barcelona, Spain: Patients with head and neck cancer and a low haemoglobin (Hb) level do not respond well to radiotherapy and therefore both control of their tumour and disease-free survival are compromised. Now researchers from The Netherlands have found that the problems caused by low Hb in these patients can ...

Chemotherapy is a major first line defense against breast cancer. However a patient's response is often variable and unpredictable. A study published in BioMed Central's open access journal BMC Medical Genomics shows that 'gene expression signatures' for TOP2A and β-tubulin can be used to predict the outcome of ...

Cancer therapies targeting specific molecular subtypes of the disease allow physicians to tailor treatment to a patient's individual molecular profile. But scientists are finding that in many types of cancer the molecular subtypes are more varied than previously thought and contain further genetic alterations that can affect a patient's response ...

Singapore scientists from Bioprocessing Technology Institute (BTI) under the Agency of Science, Technology and Research (A*STAR) have for the first time, identified the molecular 'switch' that directly triggers the body's first line of defence against pathogens, more accurately known as the body's "innate immunity". The scientists found that this 'switch' ...

How well people with newly diagnosed epilepsy respond to their first drug treatment, may signal the likelihood that they will continue to have uncontrolled seizures according to University of Melbourne Chair of Neurology Professor Patrick Kwan. In a study published in Neurology®, the medical journal of the American Academy of ...

The Food and Drug Administration (FDA) has announced that physicians should reassess patients with osteoporosis who are being treated with a class of drugs called bisphosphonates after three to five years of therapy to determine whether they should continue treatment. Bisphosphonates are a widely prescribed class of drugs that are ...

(Agency for Science, Technology and Research (A*STAR), Singapore) Singapore scientists from Bioprocessing Technology Institute under the Agency of Science, Technology and Research have for the first time, identified the molecular 'switch' that directly triggers the body's first line of defense against pathogens, more accurately known as the body's "innate immunity."

(University of North Carolina School of Medicine) A UNC-led team of scientists has shown for the first time that lung cancer molecular subtypes correlate with distinct genetic alterations and with patient response to therapy. These findings in pre-clinical models and patient tumor samples build on their previous report of three ...

By Serena Gordon HealthDay Reporter WEDNESDAY, May 9 (HealthDay News) -- The way someone responds to the first anti-seizure medication given after a diagnosis of epilepsy often predicts how well- controlled their seizures will be over time. A new study found ...